Search Articles

View query in Help articles search

Search Results (1 to 2 of 2 Results)

Download search results: CSV END BibTex RIS


Ascertaining Medication Use and Patient-Reported Outcomes via an App and Exploring Gamification in Patients With Multiple Sclerosis Treated With Interferon β-1b: Observational Study

Ascertaining Medication Use and Patient-Reported Outcomes via an App and Exploring Gamification in Patients With Multiple Sclerosis Treated With Interferon β-1b: Observational Study

In addition, the patients completed three PRO instruments every 3 months from the time of informed consent to the end of observation: the Euro Qol 5-Dimension, 5-Level questionnaire (EQ-5 D-5 L); the Treatment Satisfaction Questionnaire for Medication (TSQM; version II) [8,9]; and a questionnaire on satisfaction with the BETAPLUS PSDMP, the BETACONNECT, and the app (service questionnaire; Multimedia Appendix 1).

Volker Limmroth, Kirsten Bayer-Gersmann, Christian Mueller, Markus Schürks

JMIR Form Res 2022;6(3):e31972

Assessment of Medication Adherence Using a Medical App Among Patients With Multiple Sclerosis Treated With Interferon Beta-1b: Pilot Digital Observational Study (PROmyBETAapp)

Assessment of Medication Adherence Using a Medical App Among Patients With Multiple Sclerosis Treated With Interferon Beta-1b: Pilot Digital Observational Study (PROmyBETAapp)

In Germany, ~80% of patients with MS treated with interferon beta‑1b (Betaferon) use an electronic autoinjector (BETACONNECT; Bayer, Leverkusen, Germany), which automatically records every injection. Patients may also choose to use a medical app (my BETAapp) [14] to document injection data, which can be automatically transferred from the electronic autoinjector or entered manually.

Volker Limmroth, Klaus Hechenbichler, Christian Müller, Markus Schürks

J Med Internet Res 2019;21(7):e14373